291 related articles for article (PubMed ID: 34944914)
1. Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy.
Bullock K; Richmond A
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944914
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
3. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.
Yin K; Xia X; Rui K; Wang T; Wang S
Front Oncol; 2020; 10():610104. PubMed ID: 33384962
[TBL] [Abstract][Full Text] [Related]
5. Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling.
Zheng Y; Wang N; Wang S; Zhang J; Yang B; Wang Z
J Exp Clin Cancer Res; 2023 May; 42(1):129. PubMed ID: 37210553
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
7. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
8. Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression.
Groth C; Arpinati L; Shaul ME; Winkler N; Diester K; Gengenbacher N; Weber R; Arkhypov I; Lasser S; Petrova V; Augustin HG; Altevogt P; Utikal J; Fridlender ZG; Umansky V
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578808
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
11. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
12. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
14. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells: Therapeutic Target for Gastrointestinal Cancers.
Arshad J; Rao A; Repp ML; Rao R; Wu C; Merchant JL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474232
[TBL] [Abstract][Full Text] [Related]
16. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
Lu LC; Chang CJ; Hsu CH
J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.
Wang S; Zhao X; Wu S; Cui D; Xu Z
Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204
[TBL] [Abstract][Full Text] [Related]
19. Improving cancer immunotherapy by targeting the STATe of MDSCs.
de Haas N; de Koning C; Spilgies L; de Vries IJ; Hato SV
Oncoimmunology; 2016 Jul; 5(7):e1196312. PubMed ID: 27622051
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy.
Dong Y; Fu R; Chen J; Zhang K; Ji M; Wang M; Jiang H; Ye W; Hu J; Li Y; Jin J; Chen X; Xu H
J Med Chem; 2021 Nov; 64(22):16626-16640. PubMed ID: 34676759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
